SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
-4.4%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(-0.41%)
Cap. Flow
+$24.4M
Cap. Flow
% of AUM
2.16%
Top 10 Holdings %
Top 10 Hldgs %
36.51%
Holding
116
New
25
Increased
31
Reduced
26
Closed
23
Top Buys
| 1 |
Terns Pharmaceuticals
TERN
|
$33.7M |
| 2 |
Iovance Biotherapeutics
IOVA
|
$32.4M |
| 3 |
Praxis Precision Medicines
PRAX
|
$20.5M |
| 4 |
Nurix Therapeutics
NRIX
|
$19.6M |
| 5 |
Enliven Therapeutics
ELVN
|
$18M |
Top Sells
| 1 |
Rigel Pharmaceuticals
RIGL
|
$67.4M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$47.1M |
| 3 |
United Therapeutics
UTHR
|
$37.7M |
| 4 |
GeneDx Holdings
WGS
|
$18.2M |
| 5 |
HCA Healthcare
HCA
|
$17.2M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Consumer Staples | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
TG Therapeutics
TGTX
$4.65B
| $64.9M | 5.72% | 3,645,562 +477,106 | +15% | +$8.49M |
|
|
2
Iovance Biotherapeutics
IOVA
$807M
| $60.5M | 5.34% | 7,548,000 +4,043,000 | +115% | +$32.4M |
|
|
3
United Therapeutics
UTHR
$13.8B
| $45.1M | 3.98% | 141,499 -118,250 | -46% | -$37.7M |
|
|
4
Nurix Therapeutics
NRIX
$714M
| $42.9M | 3.78% | 2,055,916 +940,916 | +84% | +$19.6M |
|
|
EDAP
5
EDAP TMS
EDAP
$84.5M
| $39.7M | 3.5% | 7,293,728 +66,375 | +0.9% | +$361K |
|
|
6
Terns Pharmaceuticals
TERN
$609M
| $33.7M | 2.97% | +4,947,738 | New | +$33.7M |
|
7
Revolution Medicines
RVMD
$7.1B
| $33.2M | 2.93% | 856,178 +127,478 | +17% | +$4.95M |
|
8
Surmodics
SRDX
$487M
| $32.9M | 2.9% | 781,777 -19,043 | -2% | -$801K |
|
9
Organogenesis Holdings
ORGO
$653M
| $32.3M | 2.84% | 11,518,954 +1,945,756 | +20% | +$5.45M |
|
10
Jasper Therapeutics
JSPR
$45.5M
| $29M | 2.55% | 1,276,190 +89,094 | +8% | +$2.02M |
|
11
IDEAYA Biosciences
IDYA
$2.15B
| $24.4M | 2.15% | 694,069 +160,554 | +30% | +$5.64M |
|
12
Axogen
AXGN
$743M
| $23.9M | 2.11% | 3,305,815 +200,000 | +6% | +$1.45M |
|
13
Krystal Biotech
KRYS
$4.27B
| $23.1M | 2.04% | 126,000 +41,900 | +50% | +$7.69M |
|
14
Merus
MRUS
$4.98B
| $22.3M | 1.96% | 376,321 +180,744 | +92% | +$10.7M |
|
15
Penumbra
PEN
$10.6B
| $22.2M | 1.96% | 123,450 +37,750 | +44% | +$6.79M |
|
16
ESSA Pharma
EPIX
$11.4M
| $22.1M | 1.95% | 4,210,537 +620,979 | +17% | +$3.27M |
|
|
17
Praxis Precision Medicines
PRAX
$958M
| $22M | 1.94% | 533,015 +495,747 | +1,330% | +$20.5M |
|
18
Celcuity
CELC
$2.17B
| $19.8M | 1.75% | 1,211,187 -520,151 | -30% | -$8.52M |
|
|
NARI
19
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $19.7M | 1.73% | 408,373 +131,373 | +47% | +$6.33M |
|
|
ONC
20
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $19.6M | 1.73% | 137,700 -10,400 | -7% | -$1.48M |
|
21
C4 Therapeutics
CCCC
$185M
| $18.7M | 1.65% | 4,051,996 +1,593,000 | +65% | +$7.36M |
|
22
Castle Biosciences
CSTL
$696M
| $18.6M | 1.64% | 853,628 +128,171 | +18% | +$2.79M |
|
23
Neuropace
NPCE
$303M
| $18.4M | 1.62% | 2,433,168 | – | – |
|
|
24
Enliven Therapeutics
ELVN
$1.2B
| $18M | 1.59% | +769,263 | New | +$18M |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $17.4M | 1.54% | +71,700 | New | +$17.4M |
|